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outcome in acromegaly, is the application of intraoperative imaging-
guided surgery, targeted at the GHRH receptor in acromegaly, as
presently in the investigational stage for detection carcinoma remnants
during surgery (Chi et al., 2014).
Drugs for medical treatment of acromegaly are dopamine agonists,
somatostatin analogs, GH-receptor-blocking agents, GH-receptor syn-
thesis blocking agents, and GH-transcription blocking agents. At presentAcromegaly is a rare progressive endocrine disorder, with character-
istic symptoms, due to excessive growth hormone (GH) secretion from
a pituitary adenoma. Evenmore rarely, the disease can be caused by he-
reditary syndromes (multiple endocrine neoplasia type 1, McCune–
Albright syndrome, Carney complex, and familial acromegaly), ectopic
tumors or caused by tumor-related excessive GHRH secretion. The re-
ported incidence of acromegaly is 3–4 per one million per year and
the prevalence is 60 to 70 per one million, without geographical and
sex differences. The disease is likely under-diagnosed (Schneider et al.,
2008). Acromegaly leads to multisystem damage, impaired quality of
life, even in cured patients, and decreased life expectancy when not
properly treated. Since it is reasonable to assume (although not proven)
that both the duration of untreated disease and severity of GH excess
contribute to the acromegaly-associated abnormalities and organ dam-
age, efforts should be undertaken to detect patients in the population at
an early stage, to improve diagnostic procedures and further to develop
superior medicines and surgical techniques. Awareness of acromegaly
by primary health care doctors as well as by non-endocrine specialists
would likely shorten the delay in diagnosis, which is now roughly be-
tween 6 and 10 years. When the disease is suspected, the diagnosis is
made on increased age-related serum insulin-like growth factor (IGF)-
1 and insufﬁcient suppression of serum GH during glucose loading.
Treatment options are surgery, medical treatment and radiation
therapy. The current consensus is that surgery (presently mostly
2-D or 3-D endoscopic surgery, eventually with various forms of
neuronavigation) should be performed as an initial treatment by an ex-
perienced surgeon in a center with expertise of acromegaly treatment.
Normalization of GH and IGF-1 after the ﬁrst surgical treatment of acro-
megaly is obtained in 61.2% (range 37–88), based on 32 studies
(Roelfsema et al., 2011). Surgery-related pituitary insufﬁciency is low
with 7% and the overall recurrence rate 4.9%, and not related to tumor
size. A problem during surgery is the detection of small tumor rem-
nants, especially tumor outgrowth in the cavernous sinus. Careful ex-
tended exploration is one of the strategies used. Other groups have
introduced the intraoperative use of high resolutionMRIwith favorable. This is an open access article underlong-acting forms of somatostatin analogs are widely used as GH-
suppressive agents. The current clinically used slow-release analogs,
octreotide and lanreotide, inhibit GH secretion via the somatostatin re-
ceptor subtypes 2 and 5. Although themost important effect of somato-
statin analogs is the inhibition of tumor-derived GH and the subsequent
fall in circulating liver-derived IGF-I, part of the peripheral effects are
caused by the direct inhibition of IGF-I gene transcription via activation
after binding to the somatostatin receptor. Multicenter studies have
shown that disease activity is controlled in 40–60% of the patients
(Roelfsema et al., 2005). Tumor volume reduction of GH adenoma
with a weightedmean of 19.4% has been reported to occur in 62% of ac-
romegalic patients during primary therapy with somatostatin analogs
(Melmed et al., 2005). A recently marketed drug is pasireotide, which
has binding afﬁnities to all somatostatin receptor subtypes, except
SST4. The long-acting form of pasireotide requires monthly injections,
similar as the other registered long-acting somatostatin analogs. Several
phase III clinical trials comparing the efﬁcacywith other long-acting an-
alogs are currently being performed (ClinicalTrials.gov NCT00600866,
NCT00446082). All somatostatin analogs inhibit insulin secretion, but
whether glucose intolerance or frank diabetesmellituswill bemore fre-
quent or severe with pasireotide than octreotide or lanreotide is not
known yet. A potential very interesting drug (Octreolin®) uses the
Transient Permeability Enhancer (TPE) technology. The TPE system
causes temporary opening of the tight junctions of the small intestine
epithelium, allowing the passage of octreotide (or any other drug)
into the blood system. Currently, a multicenter trial is carried out
(NCT01412424). If Octreolin is successful in this relative small compet-
itive market, the treatment of persisting acromegaly is greatly simpli-
ﬁed. The use of more effective GH- or IGF-I-suppressive drugs with
this carrier system could further improve results.
The role of dopamine agonists is rather limited, and the drugs are
mostly used as an adjunct to other forms of medical treatment if IGF-I
normalization is not achieved. Cabergoline is the drug of choice and in
its present dosage does not lead to cardiac valvular dysfunction. More
effective is the GH-receptor blocking drug pegvisomant in normalizing
IGF-I, especially when GH levels are not very high, as usually found inthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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somatostatin analogs is an effective way to improve results, permitting
dose reduction of the expensive pegvisomant (van der Lely et al., 2012).
Patients require careful monitoring of liver functions and the tumor
remnant.
Several pharmaceutical companies have developed drugs aimed at
blocking the IGF receptor, including GSK 1904529A and ATL 1103, an
antisense drug. Although these drugs could be used potentially in acro-
megaly, they are primarily developed as adjunct drugs in cancer treat-
ment (Tachas et al., 2006; Sabbatini et al., 2009).
A new concept in inhibiting GH secretion is the construction of
targeted secretion inhibitors. These engineered proteins incorporate
botulinum neurotoxin and a GHRH-receptor binding domain. After
binding to the receptor, the complex is internalized in the endosome. In-
sertion of the translocation domain into the endosomal membrane al-
lows the delivery of endopeptidase into the cell, leading to cleavage of
the SNARE proteins (soluble N-ethylmaleimide-sensitive factor attach-
ment protein receptor). SNARE proteins dock and fuse GH hormone-
containing vesicles with the cell surface membrane, allowing subse-
quent GH secretion. Experimental data in rats have shown that this
class of promising drugs is a potent inhibitor of GH secretion, but the
present formulations are without GH-suppressive effect in human ade-
noma in vitro (Somm et al., 2012).
The place of radiation therapy in the treatment of acromegaly is
rather limited, and currently is only used when all other options are un-
successful in normalizing IGF-I. Radiation modalities include fractionat-
ed conventional external beam irradiationwith a linear accelerator via a
three-ﬁeld or a rotational technique. The total dose is generally
40–50 Gy, and the fractional dose 1.8–2.0 Gy. The time interval required
for normalization of GH depends on the initial level. The most frequent
side effect is hypopituitarism in up to 50% of the patients after 10 years.
The other treatmentmodality is radiosurgery. This technique is the pre-
cise stereotactic delivery of a single high radiation dose to a deﬁned tar-
get with a steep dose gradient at themargin. Radiationmay be given by
the Gamma knife, a linear accelerator (Linac)-based system or proton
beams (Minniti et al., 2011). Particularly, proton beam equipment is
very expensive, butmay be superior to other forms of radiation therapy.
Nevertheless, long-term controlled studies comparing results of the dif-
ferent treatment forms are largely lacking.In summary, there are several possible strategies for improving out-
come of treatment of acromegaly. Even if patients are cured by expert
surgery, many of them are still suffering from irreversible organ dam-
age. In an ideal world the diagnosis should be made before gross and ir-
reversible abnormalities occur. Awareness of this disease by primary
care physiciansmay lead to earlier andmore frequent diagnosis. Further
improvement of endoscopic surgery tools with equipment for detection
of small tumor remnants after removal of the gross tumor will improve
the outcome of surgery. The second generation of somatostatin receptor
blocking drugs and the GH-receptor blocking pegvisomant, although
rather effective if GH levels are not high, should be replacedmymore ef-
fective drugs. Several of these new classes of drugs with different action
mechanisms are currently under development.
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